Pyridine-nucleotide coenzyme (not a peptide)
NAD+
Nicotinamide adenine dinucleotide (oxidised form) — a pyridine-nucleotide coenzyme (NOT a peptide) central to redox biology, sirtuin activation, and PARP-mediated DNA repair
Overview
Before anything else about NAD+ is worth saying, one editorial point has to be stated clearly: NAD+ is not a peptide. It is nicotinamide adenine dinucleotide — a pyridine-nucleotide coenzyme composed of two nucleotides linked through their phosphate groups. Peptides are chains of amino acids; NAD+ is not that. It is included in this catalog because the Healthy Mango PDF covers it alongside peptides as a practical injectable in the same wellness clinic setting, not because it belongs to the same molecular class.
With that framing established, the biology of NAD+ is genuinely fundamental. It sits at multiple central nodes of cellular metabolism. As a redox carrier, NAD+ / NADH cycling drives electron transport chain ATP synthesis — every calorie of aerobic energy your cells produce moves through the NAD+ pool. As a co-substrate, NAD+ is consumed by the sirtuin family of deacetylases (SIRT1 through SIRT7), which regulate gene expression, mitochondrial biogenesis (via the transcriptional coactivator PGC-1α), inflammation, and DNA-damage responses. It is also consumed by PARP-1 during DNA-strand-break repair and by CD38 during immune-cell calcium signalling. Because sirtuins, PARP-1 and CD38 all draw from the same NAD+ pool, cellular NAD+ availability sits at the intersection of energy metabolism, gene expression, DNA repair and immune function.
The age-related NAD+ decline story is what drives most of the current commercial interest. Multiple studies have documented that tissue NAD+ levels fall with age in humans and animals; that fall is thought to contribute to reduced sirtuin activity, mitochondrial dysfunction, and impaired DNA repair. The therapeutic hypothesis is that raising NAD+ levels — either by direct NAD+ administration or via metabolic precursors — could reverse some of the metabolic and DNA-repair consequences of the age-related decline. That hypothesis has produced an enormous supplement industry around oral nicotinamide riboside (NR, marketed as Niagen® by ChromaDex) and nicotinamide mononucleotide (NMN), a smaller injectable IV clinic industry around direct NAD+ administration, and considerable academic interest that has not yet produced definitive age-related outcome trials.
The regulatory picture is unusual. Injectable NAD+ has no FDA approval for any therapeutic indication. IV NAD+ programmes are typically run through compounding pharmacies and IV clinics as off-label offerings; the practice traces back to Paul O'Hollaren and Paul Hitt's work in the 1960s using intravenous NAD+ in addiction recovery, a use that has continued in some settings but never been approved. Oral NR is authorised as a novel food in the EU (2019 EFSA opinion) and is widely sold as a supplement in the US; NMN's supplement status in the US has been questioned by the FDA but not fully clarified. The compound sits in an unusual regulatory space where it is simultaneously sold as a supplement, administered off-label in clinics, and studied in academic pharmacology labs, without a coherent approved-therapeutic identity.
Quick Facts & Evidence
- Category
- Pyridine-nucleotide coenzyme (not a peptide)
- Research area
- Coenzyme
- Most studied for
- Sirtuin biology and gene expression regulation
- Mitochondrial biogenesis via PGC-1α
- DNA repair via PARP-1
- Immune cell signalling via CD38
- Age-related metabolic decline
- Addiction (historical Hitt IV NAD+ programme)
- Cognitive support
- Clinical status
- Research use only — no approved clinical indication
- Human evidence
- Early Human Evidence
- Regulatory status
- Not approved by FDA, EMA or MHRA
Early Human Evidence
Small-scale human studies, observational data, or off-label case reports only. Substantial uncertainty remains.
Research Protocols
Research Protocol Snapshot
Preparation covered on this page
Freeze-dried injectable research format (adjusted pH)
This page covers the RUO lyophilized NAD+ vial (adjusted pH) reconstituted with bacteriostatic water for subcutaneous research use, following the standard Healthy Mango preparation convention. NAD+ is a pyridine-nucleotide coenzyme, not a peptide; it is covered here because the practitioner reference includes it alongside peptides as a practical injectable.
NAD+ research values at a glance.
| Item | Example value |
|---|---|
| Vial size | 500 mg |
| Liquid used to mix | Bacteriostatic water |
| Amount of liquid added | 5.0 mL |
| Final concentration | 100 mg/mL |
| How it's given | Subcutaneous injection, slowly over 30–60 seconds |
| Research dose | 50 mg (range 50–200 mg) |
| Frequency | 2 times per week |
| Duration | Continuous — no cycling rationale |
Reported Dosing
The practitioner-reference research protocol for NAD+ is 50 mg per subcutaneous injection (range 50–200 mg), twice per week, injected slowly over 30–60 seconds, run continuously. It is educational reference, not a recommendation.
The Reported Protocol
| Dose | Frequency | Duration | Notes |
|---|---|---|---|
| 50 mg (range 50–200 mg) | 2×/week, subcutaneous, slow push over 30–60 s | Continuous — no cycling rationale | 0.5–2.0 mL at 100 mg/mL; adjusted-pH formulation |
Why protocols vary
NAD+ is produced and consumed by every cell continuously as a coenzyme; the pharmacology is substrate replenishment rather than receptor pulsatility. No cycling rationale exists — the compound is used continuously in the practitioner reference.
The slow-push technique (30–60 seconds) exists because a rapid injection causes transient flushing, warmth, and nausea. Those effects are a function of injection speed, not of the compound itself.
The adjusted-pH formulation is what makes subcutaneous NAD+ tolerable — historic IV NAD+ complaints trace to pH issues in older formulations rather than to the coenzyme itself.
Preparing the Solution
Turning the freeze-dried powder into a measurable liquid.
Documented preparation
The documented research protocol is based on this preparation concentration.
Freeze-dried powder: 500 mg vial
Diluent: 5.0 mL bacteriostatic water
Final concentration: 100 mg/mL
Vial and volume from the practitioner reference; concentration calculated · Research-practitioner guide
Your vial
Matching preparation
Bacteriostatic water
5mL
Resulting concentration
100 mg/mL
Equivalent volume
The reported research amount of 50–200 mg is contained within
0.5–2.0mL
of the prepared solution now in your vial.
Show calculation
- Documented concentration
- 500 mg ÷ 5 mL = 100 mg/mL
- Bacteriostatic water to match the documented concentration
- 500 mg ÷ 100 mg/mL = 5 mL
- Equivalent volume at this concentration
- 50–200 mg ÷ 100 mg/mL = 0.5–2 mL
This tool performs arithmetic conversions using the preparation example and reported research amount shown on this page. It does not recommend an amount, route, preparation method, or use.
This tool performs arithmetic conversions using the preparation example and reported research amount shown on this page. It does not recommend an amount, route, preparation method, or use.Sources for these values
- Documented in the practitioner referenceResearch-practitioner guide
This example explains how concentration and volume are calculated for the standard RUO preparation. It is not a preparation guide.
How It's Given
Method used for this format
Subcutaneous injection, twice weekly, slow push over 30–60 seconds
Documented in the practitioner reference · Research-practitioner guide
Why this method
Injectable NAD+ bypasses the gastrointestinal degradation and CD38-driven consumption that reduce oral NAD-precursor bioavailability, delivering the coenzyme systemically.
The slow push is a technique choice, not a mechanism choice — a rapid injection triggers transient flushing that fast administration alone can avoid.
Injection sites reported
- Abdomen (rotate sites)
- Front of the thigh
- Back of the upper arm
- Avoid scarred, bruised, inflamed, or infected skin
Storage
Before mixing
- Refrigerate 2–8 °C
- Protect from light
- Do not freeze
General RUO practice · Research-practitioner guide
After mixing
- Refrigerate 2–8 °C
- Use within 7–10 days
- Do not freeze
- Discard if cloudy or discoloured
General RUO practice · Research-practitioner guide
Handling
- Direct diluent slowly down the vial wall
- Gently swirl until dissolved — do not shake
- New sterile needle each draw
- Slow push over 30–60 seconds
Documented in the practitioner reference · Research-practitioner guide
Storage guidance summarises standard RUO handling for the adjusted-pH lyophilized presentation. Pre-mixed pH-adjusted liquid formulations follow their own product-specific storage windows.
Common Cycle
The practitioner reference frames NAD+ as continuous twice-weekly dosing without a washout rationale.
- Cycle Length
- Continuous 2×/week
- Break Before the Next Cycle
- No cycling — continuous use
- What the Research Shows
- No large controlled human trial has evaluated injectable-NAD+ long-term outcomes
Documented in the practitioner reference · Research-practitioner guide
NAD-precursor trials (NR, NMN) are mechanistically related but do not substitute for injectable NAD+ evidence; each preparation has its own bioavailability profile.
Compound Overview
Current areas of research
Reported effects. NAD+'s biology is well-characterised; specific clinical outcomes remain under-studied at scale.
- Sirtuin activation supporting gene expression, mitochondrial biogenesis and DNA repair
- PARP-1-mediated DNA strand-break repair (NAD+ is the substrate)
- Cellular energy metabolism support via electron transport chain
- Subjectively reported energy and mental clarity during and after administration
- Preclinical extension of healthspan in aged animal models treated with precursors
Mechanism of action
Before anything else about NAD+ is worth saying, one editorial point has to be stated clearly: NAD+ is not a peptide. It is nicotinamide adenine dinucleotide — a pyridine-nucleotide coenzyme composed of two nucleotides linked through their phosphate groups. Peptides are chains of amino acids; NAD+ is not that. It is included in this catalog because the Healthy Mango PDF covers it alongside peptides as a practical injectable in the same wellness clinic setting, not because it belongs to the same molecular class.
With that framing established, the biology of NAD+ is genuinely fundamental. It sits at multiple central nodes of cellular metabolism. As a redox carrier, NAD+ / NADH cycling drives electron transport chain ATP synthesis — every calorie of aerobic energy your cells produce moves through the NAD+ pool. As a co-substrate, NAD+ is consumed by the sirtuin family of deacetylases (SIRT1 through SIRT7), which regulate gene expression, mitochondrial biogenesis (via the transcriptional coactivator PGC-1α), inflammation, and DNA-damage responses. It is also consumed by PARP-1 during DNA-strand-break repair and by CD38 during immune-cell calcium signalling. Because sirtuins, PARP-1 and CD38 all draw from the same NAD+ pool, cellular NAD+ availability sits at the intersection of energy metabolism, gene expression, DNA repair and immune function.
The age-related NAD+ decline story is what drives most of the current commercial interest. Multiple studies have documented that tissue NAD+ levels fall with age in humans and animals; that fall is thought to contribute to reduced sirtuin activity, mitochondrial dysfunction, and impaired DNA repair. The therapeutic hypothesis is that raising NAD+ levels — either by direct NAD+ administration or via metabolic precursors — could reverse some of the metabolic and DNA-repair consequences of the age-related decline. That hypothesis has produced an enormous supplement industry around oral nicotinamide riboside (NR, marketed as Niagen® by ChromaDex) and nicotinamide mononucleotide (NMN), a smaller injectable IV clinic industry around direct NAD+ administration, and considerable academic interest that has not yet produced definitive age-related outcome trials.
The regulatory picture is unusual. Injectable NAD+ has no FDA approval for any therapeutic indication. IV NAD+ programmes are typically run through compounding pharmacies and IV clinics as off-label offerings; the practice traces back to Paul O'Hollaren and Paul Hitt's work in the 1960s using intravenous NAD+ in addiction recovery, a use that has continued in some settings but never been approved. Oral NR is authorised as a novel food in the EU (2019 EFSA opinion) and is widely sold as a supplement in the US; NMN's supplement status in the US has been questioned by the FDA but not fully clarified. The compound sits in an unusual regulatory space where it is simultaneously sold as a supplement, administered off-label in clinics, and studied in academic pharmacology labs, without a coherent approved-therapeutic identity.
- Nicotinamide adenine dinucleotide — a coenzyme, NOT a peptide. Included because the Healthy Mango PDF covers it as a practical injectable, not because it shares molecular class with the other compounds
- Central to cellular energy (electron transport chain), sirtuin activation (SIRT1–7), DNA repair (PARP-1) and immune signalling (CD38)
- No FDA-approved injectable therapeutic; oral precursors (NR, NMN) are sold as supplements; IV NAD+ is a grey-market/off-label clinic offering
Human research
The Verdin 2015 Science review synthesises the modern mechanistic picture of NAD+ biology — sirtuin activation, PARP substrate role, CD38 consumption, age-related decline. It is a good framework document.
Imai and Guarente's 2014 Trends in Endocrinology and Metabolism review covers the specific NAD+ – sirtuin – ageing axis and the therapeutic implications.
The Trammell 2016 Nature Communications paper characterises nicotinamide riboside pharmacokinetics in humans, establishing that oral NR does raise blood NAD+ metabolites.
Yoshino et al. 2021 reported the first randomised placebo-controlled clinical trial of NMN in postmenopausal women, showing metabolic improvements. The clinical outcome literature is developing.
The historical Hitt IV NAD+ addiction work traces back to the 1960s and represents the origin of injectable NAD+ clinical use, but is largely outside modern academic pharmacology.
Verdin 2015 Science review
Consolidating review of modern NAD+ biology — sirtuin activation, PARP substrate role, CD38 consumption, age-related decline. The framework document.
Imai & Guarente 2014
Review of the NAD+ – sirtuin – ageing axis and its therapeutic implications.
Trammell 2016 (NR pharmacokinetics)
Human PK study of oral nicotinamide riboside showing dose-dependent elevation of blood NAD+ metabolites.
Yoshino 2021 (NMN clinical)
Randomised placebo-controlled clinical trial of NMN in postmenopausal women showing metabolic improvements.
Hitt IV NAD+ addiction work (1961)
Historic origin of injectable NAD+ clinical use in addiction recovery. Referenced for historical continuity rather than modern-standard evidence.
Injectable NAD+ has no FDA-approved therapeutic indication. IV NAD+ clinics operate as off-label compounded-medicine businesses; oral NAD+ precursors (NR, NMN) are sold as supplements. The compound's central biological role in cellular metabolism is well-established; specific approved-therapeutic outcomes are not.
The historical IV NAD+ programme in addiction recovery (O'Hollaren, Hitt and colleagues in the 1960s and beyond) is a genuine clinical tradition but has never been formalised into a phase-3 approved therapy.
Recent phase-1/2 clinical trials of oral NR and NMN have demonstrated safe elevation of blood NAD+ metabolites in humans. Whether that elevation translates into meaningful clinical outcomes on age-related endpoints remains an open question with active ongoing research.
Safety considerations
Adverse events reported in clinical experience.
- Flushing, warmth, and mild nausea during rapid administration — Dramatically reduced with slow injection over 30–60 seconds
- Chest pressure sensation with rapid IV administration
- Injection-site reactions
- Very well-tolerated when administered slowly at standard doses
No approved-label warnings exist. Considerations below draw on the compound's biology.
- Active malignancy or concurrent chemotherapy — discuss with oncologist given PARP-1 substrate role in DNA-damage response
- Autoimmune conditions — theoretical caution given CD38 immune modulation
- Pregnancy — inadequate injectable safety data
- Not FDA-approved as an injectable therapeutic anywhere
Monitoring
- Injection-site reactions
- Systemic tolerability (flushing, chest pressure, nausea)
- Subjective energy / cognitive response
Frequently asked questions
Is NAD+ a peptide?
No. NAD+ is a pyridine-nucleotide coenzyme — chemically a dinucleotide, not an amino-acid chain. Peptides are chains of amino acids. NAD+ is included in this catalog because the Healthy Mango PDF covers it as a practical injectable in the same wellness setting as its peptide chapters, not because it shares molecular class with peptides.
What's the difference between NAD+, NR and NMN?
NAD+ is the coenzyme itself. NR (nicotinamide riboside) and NMN (nicotinamide mononucleotide) are metabolic precursors that the body converts into NAD+. Oral NR and NMN raise blood and tissue NAD+ metabolites; direct injectable NAD+ raises circulating NAD+ acutely. The precursors are sold as supplements; the injectable NAD+ is a grey-market off-label offering. Which route produces meaningful clinical outcomes is an active research question.
Why does NAD+ injection cause flushing and nausea?
These are rate-dependent effects, not compound-intrinsic. Rapid administration produces flushing, warmth, chest pressure sensation and nausea. Slow administration over 30–60 seconds subcutaneously, or slow IV drip over 1–4 hours, dramatically reduces these effects. Older unbuffered NAD+ preparations also produced injection-site pain from non-physiological pH; the 'pH-adjusted' modern formulations reduce this.
Does NAD+ actually reverse aging?
The biology is real and consequential — NAD+ is central to sirtuin activation, DNA repair and mitochondrial function, and cellular NAD+ levels decline with age. Whether raising NAD+ levels reverses meaningful clinical outcomes in humans is a different question. Preclinical work in aged mice with NAD+ precursors has shown healthspan effects; human phase-1/2 trials have shown that oral precursors do raise blood NAD+ metabolites; phase-3 clinical outcome trials have not yet demonstrated that this translates into definitive age-related benefits. 'Reversing aging' is well beyond what the current evidence supports.
Is NAD+ safe with chemotherapy?
NAD+ is the substrate consumed by PARP-1 during DNA-strand-break repair. Some cancer therapies work by exploiting cancer cells' DNA-damage response (PARP inhibitors are a prominent example). Whether concurrent NAD+ supplementation would interact with those therapies is not fully characterised. Anyone on active chemotherapy or PARP-directed therapy should discuss any NAD+ use with their oncologist.
References
- [1]
NAD+ in aging, metabolism, and neurodegeneration — mechanistic consolidating review — Verdin E, Science (2015)
- [2]
NAD+ and sirtuins in aging and disease — the therapeutic axis — Imai S-i, Guarente L, Trends in Endocrinology and Metabolism (2014)
- [3]
Historic IV NAD+ programme in addiction recovery — the O'Hollaren / Hitt clinical tradition — O'Hollaren PM, Hitt WC, Western Journal of Medicine (historical) (1961)
- [4]
Nicotinamide riboside is uniquely and orally bioavailable in mice and humans — first pharmacokinetic characterisation — Trammell SAJ, Schmidt MS, Weidemann BJ, et al., Nature Communications (2016)
- [5]
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women — first randomised placebo-controlled human clinical trial of NMN — Yoshino M, Yoshino J, Kayser BD, et al., Science (2021)
- [6]
Peptides & Compounds — The No-Jargon Guide (v5) — Healthy Mango Editorial, Healthy Mango practitioner reference (2026)
Laboratory Reference Notice
This section summarizes procedures and study parameters reported in published scientific literature and laboratory protocols. It is provided for educational and research reference only and must not be interpreted as medical advice, clinical guidance, or instructions for personal use.
Editorial review pending
This page has not yet undergone external editorial review. Content is drawn from published sources and may be updated as review completes.